Trials / Completed
CompletedNCT04863131
Safety and Immunogenicity of EXG-5003
Safety and Immunogenicity of Intradermal SARS-CoV-2 Vaccine EXG-5003 in Healthy Adults
- Status
- Completed
- Phase
- Phase 1 / Phase 2
- Study type
- Interventional
- Enrollment
- 40 (actual)
- Sponsor
- Fujita Health University · Academic / Other
- Sex
- All
- Age
- 20 Years – 55 Years
- Healthy volunteers
- Accepted
Summary
This is a First in Human, randomized, placebo-controlled Phase I/II trial to evaluate the safety and immunogenicity of the intradermal COVID-19 vaccine, EXG-5003 in healthy adults.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | EXG-5003 | COVID-19 self-replicating mRNA vaccine |
| BIOLOGICAL | Placebo | placebo solution |
Timeline
- Start date
- 2021-04-28
- Primary completion
- 2022-12-31
- Completion
- 2023-01-24
- First posted
- 2021-04-28
- Last updated
- 2023-01-26
Locations
1 site across 1 country: Japan
Source: ClinicalTrials.gov record NCT04863131. Inclusion in this directory is not an endorsement.